Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04692311
Other study ID # i-ACT pilot
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 4, 2016
Est. completion date August 31, 2016

Study information

Verified date December 2020
Source PXL University College
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The pilot study was performed to evaluate the usability, credibility and expectancy of an intelligent, activity-based client-centred training system (i-ACT), and the motivation towards its use in neurological rehabilitation over a short period of time.


Description:

A mixed-method study was performed in four rehabilitation centres in Belgium. An homogenous convenience sample was recruited among persons with central nervous system disorders. Participants received 3 x 45 minutes of training with the i-ACT system during six weeks, additional to conventional care. The Canadian Occupational Performance Measure (COPM) was used to collect and evaluate patients' individual goals towards rehabilitation. These goals were discussed with the therapists before implementing movements and exercises for each patient in the i-ACT system. The following demographic data were obtained from the medical files: age, gender, and diagnosis. Outcomes measures were collected at baseline (T0), after 2 (T1), 4 (T2) and 6 (T3) weeks of training and at 9 weeks follow-up (T4). The primary outcome measures were the Intrinsic Motivation Inventory (IMI), the System Usability Scale (SUS), Credibility/Expectancy Questionnaire (CEQ), the Canadian Occupational Performance Measure (COPM), and Wolf Motor Function Test (WMFT). The secondary measures were the Manual Ability Measure-36 (MAM-36), Modified Fatigue Impact Scale (MFIS), Trunk Impairment Scale (TIS), and Active Range of Motion (AROM). After final training with i-ACT, a semi-structured interview was performed to gather more information about the participants' perception towards i-ACT. For quantitative data, within-group differences of all the assessments were analysed using Friedman's ANOVA and Wilcoxon signed-rank test. Alpha was set at 0.05; No Bonferroni correction was applied as it is not compulsory in an exploratory study and furthermore, results are regarded as hypothesis for further investigations. The qualitative data was collected and recorded with a voice recorder. No specific analysis was used as the interview collected data to support or oppose the findings of the quantitative data.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date August 31, 2016
Est. primary completion date August 31, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - age over 18 years old - a medical diagnosis of central nervous system disease - dysfunction in upper limb and/or core stability - Persons with multiple sclerosis (MS) had to be free of treatment with corticosteroids for one month. - Persons with stroke or spinal cord injury, had to be at least three months post injury. Exclusion Criteria: - severe spasticity (when spasticity impedes movement) - severe cognitive impairment (person is not able to understand and follow instructions) - severe communicative impairment (person is not able to answer questions) - severe visual impairment (person is not able to see the television screen) - persons who use an electric wheelchair

Study Design


Intervention

Device:
an intelligent client-centred task-oriented training
3 x 45min of training with i-ACT system
Other:
Semi-structured interview
Participants, patients and therapists, were invited to a semi-structured interview after training period.

Locations

Country Name City State
n/a

Sponsors (7)

Lead Sponsor Collaborator
PXL University College Hasselt University, Hogeschool West-Vlaanderen, Jessa Hospital, Revalidatie & MS Centrum Overpelt, Universitaire Ziekenhuizen Leuven, Ziekenhuis Oost-Limburg

Outcome

Type Measure Description Time frame Safety issue
Primary Intrinsic Motivation Inventory Motivation towards a therapy, in this i-ACT 2 weeks
Primary Intrinsic Motivation Inventory Motivation towards a therapy, in this i-ACT 4 weeks
Primary Intrinsic Motivation Inventory Motivation towards a therapy, in this i-ACT 6 weeks
Primary Intrinsic Motivation Inventory Motivation towards a therapy, in this i-ACT 12 weeks (i.e. 6 weeks follow-up)
Primary System Usability Scale Usability of a system, in this i-ACT. Range of scores from 0 (negative) to 100 (positive). 2 weeks
Primary System Usability Scale Usability of a system, in this i-ACT. Range of scores from 0 (negative) to 100 (positive). 4 weeks
Primary System Usability Scale Usability of a system, in this i-ACT. Range of scores from 0 (negative) to 100 (positive). 6 weeks
Primary System Usability Scale Usability of a system, in this i-ACT. Range of scores from 0 (negative) to 100 (positive). 12 weeks (i.e. 6 weeks follow-up)
Primary Credibility/Expectancy Questionnaire Credibility and expectancy of a training system, in this i-ACT. The range of scores on each subscale (i.e. credibility and expectancy) is 27. 2 weeks
Primary Credibility/Expectancy Questionnaire Credibility and expectancy of a training system, in this i-ACT. The range of scores on each subscale (i.e. credibility and expectancy) is 27. 4 weeks
Primary Credibility/Expectancy Questionnaire Credibility and expectancy of a training system, in this i-ACT. The range of scores on each subscale (i.e. credibility and expectancy) is 27. 6 weeks
Primary Credibility/Expectancy Questionnaire Credibility and expectancy of a training system, in this i-ACT. The range of scores on each subscale (i.e. credibility and expectancy) is 27. 12 weeks (i.e. 6 weeks follow-up)
Primary Canadian Occupational Performance Measure By means of a semi-structured interview, participants are asked to identify their 5 main goals in self-care, productivity and/or leisure.
Scores range from 0 to 10 (best score) in each defined goal.
Baseline
Primary Canadian Occupational Performance Measure By means of a semi-structured interview, participants are asked to identify their 5 main goals in self-care, productivity and/or leisure.
Scores range from 0 to 10 (best score) in each defined goal.
4 weeks
Primary Canadian Occupational Performance Measure By means of a semi-structured interview, participants are asked to identify their 5 main goals in self-care, productivity and/or leisure.
Scores range from 0 to 10 (best score) in each defined goal.
6 weeks
Primary Canadian Occupational Performance Measure By means of a semi-structured interview, participants are asked to identify their 5 main goals in self-care, productivity and/or leisure.
Scores range from 0 to 10 (best score) in each defined goal.
12 weeks (i.e. 6 weeks follow-up)
Primary Wolf Motor Function Test Arm-hand functioning. The test contains 17 items and are scored from 0 (not able to perform tesk) to 5 (normal performance). Baseline
Primary Wolf Motor Function Test Arm-hand functioning. The test contains 17 items and are scored from 0 (not able to perform tesk) to 5 (normal performance). 2 weeks
Primary Wolf Motor Function Test Arm-hand functioning. The test contains 17 items and are scored from 0 (not able to perform tesk) to 5 (normal performance). 4 weeks
Primary Wolf Motor Function Test Arm-hand functioning. The test contains 17 items and are scored from 0 (not able to perform tesk) to 5 (normal performance). 6 weeks
Primary Wolf Motor Function Test Arm-hand functioning. The test contains 17 items and are scored from 0 (not able to perform tesk) to 5 (normal performance). 12 weeks (i.e. 6 weeks follow-up)
Secondary Manual Ability Measure-36 Manual ability. Scores range from 0 (impossible to perform) to 4 (easy to perform) Baseline
Secondary Manual Ability Measure-36 Manual ability. Scores range from 0 (impossible to perform) to 4 (easy to perform) 2 weeks
Secondary Manual Ability Measure-36 Manual ability. Scores range from 0 (impossible to perform) to 4 (easy to perform) 4 Weeks
Secondary Manual Ability Measure-36 Manual ability. Scores range from 0 (impossible to perform) to 4 (easy to perform) 6 weeks
Secondary Manual Ability Measure-36 Manual ability. Scores range from 0 (impossible to perform) to 4 (easy to perform) 12 weeks (i.e. 6 weeks follow-up)
Secondary Modified Fatigue Impact Scale Fatigue. Twenty-one items ar scored on a 5-point Likert scale (range from 0, never, to 4, almost always). The higher the score the most impact fatigue has on the life of the person. . Baseline
Secondary Modified Fatigue Impact Scale Fatigue. Twenty-one items ar scored on a 5-point Likert scale (range from 0, never, to 4, almost always). The higher the score the most impact fatigue has on the life of the person. . 2 weeks
Secondary Modified Fatigue Impact Scale Fatigue. Twenty-one items ar scored on a 5-point Likert scale (range from 0, never, to 4, almost always). The higher the score the most impact fatigue has on the life of the person. . 4 weeks
Secondary Modified Fatigue Impact Scale Fatigue. Twenty-one items ar scored on a 5-point Likert scale (range from 0, never, to 4, almost always). The higher the score the most impact fatigue has on the life of the person. . 6 weeks
Secondary Modified Fatigue Impact Scale Fatigue. Twenty-one items ar scored on a 5-point Likert scale (range from 0, never, to 4, almost always). The higher the score the most impact fatigue has on the life of the person. . 12 weeks (i.e. 6 weeks follow-up)
Secondary Trunk Impairment Scale Trunk impairment. Scores range from 0 (minimum) to 23. The higher the score the less motor impairment is present in the trunk. Baseline
Secondary Trunk Impairment Scale Trunk impairment. Scores range from 0 (minimum) to 23. The higher the score the less motor impairment is present in the trunk. 2 weeks
Secondary Trunk Impairment Scale Trunk impairment. Scores range from 0 (minimum) to 23. The higher the score the less motor impairment is present in the trunk. 4 weeks
Secondary Trunk Impairment Scale Trunk impairment. Scores range from 0 (minimum) to 23. The higher the score the less motor impairment is present in the trunk. 6 weeks
Secondary Trunk Impairment Scale Trunk impairment. Scores range from 0 (minimum) to 23. The higher the score the less motor impairment is present in the trunk. 12 weeks (i.e. 6 weeks follow-up)
Secondary Active Range of Motion Active range of motion Baseline
Secondary Active Range of Motion Active range of motion 2 weeks
Secondary Active Range of Motion Active range of motion 4 weeks
Secondary Active Range of Motion Active range of motion 6 weeks
Secondary Active Range of Motion Active range of motion 12 weeks (i.e. 6 weeks follow-up)
See also
  Status Clinical Trial Phase
Recruiting NCT05778279 - Role of New High Resolution Ultrasonographic Modalities for Diagnosis of Fetal Nervous System Anomalies
Completed NCT00116337 - Spinal Cord Stimulation to Restore Cough N/A
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Recruiting NCT05590884 - Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age Phase 2
Recruiting NCT06010823 - Safety and Efficacy Evaluation of the Robotic Enhanced Error Training of Upper Limb Function in Post-stroke and Post TBI Participants N/A
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Completed NCT01211873 - Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions Phase 3
Completed NCT00395460 - Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients Phase 3
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Recruiting NCT05968976 - Multicentre RCT of Awake Versus Asleep Tractography Based DBS for ET N/A
Not yet recruiting NCT05892510 - Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke Phase 2/Phase 3
Suspended NCT04912115 - Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia Phase 2
Completed NCT03994822 - pRESET for Occlusive Stroke Treatment N/A
Completed NCT04283253 - Predictors of Response in Chronic Stroke N/A
Completed NCT02684825 - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke N/A
Completed NCT02368223 - Feasibility of the Portable YouGrabber System N/A
Completed NCT05815836 - Precision Medicine in Stroke
Completed NCT01445639 - Dexmedetomidine in Patients After Intracranial Surgery Phase 4
Completed NCT00995215 - Sub-study to Spinal Cord Stimulation to Restore Cough N/A